Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
180 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016', provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics and enlists all their major and minor projects - The report assesses Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10 Therapeutics Development 11 Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 12 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 18 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 20 Alvogen Korea Co., Ltd. 20 AnGes MG, Inc. 21 AstraZeneca Plc 22 Athersys, Inc. 23 Bayer AG 24 Betagenon AB 25 CardioVascular BioTherapeutics, Inc. 26 Celgene Corporation 27 Hemostemix Ltd 28 ID Pharma Co., Ltd. 29 Juventas Therapeutics, Inc. 30 miRagen Therapeutics, Inc. 31 Multi Gene Vascular Systems Ltd 32 Nuo Therapeutics, Inc. 33 Proteon Therapeutics, Inc. 34 Recardio GmbH 35 Resverlogix Corp. 36 Sigma-Tau S.p.A. 37 Stemedica Cell Technologies, Inc. 38 Symic Biomedical, Inc. 39 Theravasc, Inc. 40 ViroMed Co., Ltd. 41 Yuyu Pharma, Inc. 42 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 48 Assessment by Molecule Type 50 Drug Profiles 52 ACP-01 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 AEM-28 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ALD-301 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Annexin A-5 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 apabetalone - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 beperminogene perplasmid - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 CVBT-141C - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 DVC-10101 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ELS-140 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 JVS-100 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 levocarnitine propionate hydrochloride - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 MGN-6114 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 MultiGeneAngio - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 O-304 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 PDA-002 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 PF-05285401 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 REC-03 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Rejuveinix - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 rivaroxaban - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 sarpogrelate SR - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 SB-030 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 sodium nitrite SR - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 ticagrelor - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 TXA-127 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 V-10 - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 VM-202 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 vonapanitase - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 YY-984 - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 113 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 165 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 169 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 170 Featured News & Press Releases 170 Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease 170 Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease 170 Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 171 Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 172 Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 173 Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 173 Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 174 Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 175 Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 177 Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 177 Appendix 179 Methodology 179 Coverage 179 Secondary Research 179 Primary Research 179 Expert Panel Validation 179 Contact Us 179 Disclaimer 180
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Development by Companies, H1 2016 (Contd..1) 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Comparative Analysis by Unknown Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Alvogen Korea Co., Ltd., H1 2016 20 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG, Inc., H1 2016 21 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H1 2016 22 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H1 2016 23 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2016 24 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2016 25 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016 26 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H1 2016 27 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H1 2016 28 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co., Ltd., H1 2016 29 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics, Inc., H1 2016 30 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H1 2016 31 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2016 32 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H1 2016 33 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H1 2016 34 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2016 35 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H1 2016 36 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau S.p.A., H1 2016 37 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 38 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical, Inc., H1 2016 39 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H1 2016 40 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H1 2016 41 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma, Inc., H1 2016 42 Assessment by Monotherapy Products, H1 2016 43 Number of Products by Stage and Target, H1 2016 45 Number of Products by Stage and Mechanism of Action, H1 2016 47 Number of Products by Stage and Route of Administration, H1 2016 49 Number of Products by Stage and Molecule Type, H1 2016 51 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H1 2016 113 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2016 165 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H1 2016 166 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..2), H1 2016 167 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..3), H1 2016 168 Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2016 169
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
